Published online Dec 15, 2014. doi: 10.4251/wjgo.v6.i12.444
Revised: October 28, 2014
Accepted: October 31, 2014
Published online: December 15, 2014
Processing time: 289 Days and 15.5 Hours
AIM: To evaluate the potential prognostic value of GNAS1 T393C polymorphism in advanced non-small cell lung cancer.
METHODS: We extracted genomic DNA from the peripheral blood leucocytes of 94 patients with advanced non-small cell lung cancer. Quantitative real-time polymerase chain reaction was used to determine the allelic discrimination. The correlation between genotype and overall survival was evaluated using the multivariate analysis and Kaplan-Meier approach.
RESULTS: Thirty-eight out of 94 (40%) patients displayed a TT genotype, 29 out of 94 (31%) a CT genotype and 27 out of 94 (29%) a CC genotype. The median survival of TT (25 mo) genotype carriers was longer than CT (12 mo) or CC (8 mo) genotype carriers. The favorable TT genotype predicted better overall survival (OS) (2-year OS: 48%; P =0.01) compared with CT (2-year OS: 18%) or CC (2-year OS: 15%) genotype. However, dichotomization between C-genotypes (CC + CT) and T-genotypes (TT) revealed significantly lower survival rates (2-year OS: 16%; P = 0.01) for C allele carriers.
CONCLUSION: Our data provided strong evidence that the GNAS1 T393C genetic polymorphism influenced the prognosis in advanced non-small lung cancer with a worse outcome for C allele carriers.
Core tip: We genotyped GNAS1 T393C single nucleotide polymorphism in a homogenous (Han) study population of patients to evaluate the effect of this polymorphism on survival in non-small cell lung cancer (NSCLC). Our study indicated that the GNAS1 T393C polymorphism affected the overall survival in advanced NSCLC with a worse outcome for C allele carriers.